Harpoon Therapeutics, Inc. (HARP)
Company Description
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States.
The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors.
Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors.
Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | Feb 8, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 45 |
| CEO | Ms. Julie M. Eastland M.B.A. |
Contact Details
Address:
131 Oyster Point Boulevard, Suite 300 South San Francisco, California 94080 United States | |
| Phone | 650-443-7400 |
| Website | harpoontx.com |
Stock Details
| Ticker Symbol | HARP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001708493 |
| CUSIP Number | 41358P106 |
| ISIN Number | US41358P1066 |
| Employer ID | 47-3458693 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Julie M. Eastland M.B.A. | President, Chief Executive Officer and Director |
| Dr. Natalie R. Sacks M.D. | Consultant |
| Georgia L. Erbez | Consultant |
| Dr. Holger Wesche Ph.D. | Chief Scientific Officer |
| Wendy Chang | Senior Vice President of Human Resources |
| Rachael Lester | Senior Vice President of Business Development and Corporate Strategy |
| Dr. Banmeet Anand Ph.D. | Senior Vice President of Translational Medicine |
| Dr. Luke N. Walker M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 30, 2023 | EFFECT | Notice of Effectiveness |
| May 30, 2023 | 424B3 | Prospectus |
| May 19, 2023 | S-3 | Registration statement under Securities Act of 1933 |
| May 16, 2023 | 424B5 | Filing |
| May 15, 2023 | EFFECT | Notice of Effectiveness |
| May 12, 2023 | 8-K | Current Report |
| May 11, 2023 | 10-Q | Quarterly Report |
| May 11, 2023 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Apr 27, 2023 | ARS | Filing |
| Apr 27, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |